Photopharmics
Salt Lake City, US · Founded 2011 · Delaware corporation · 1 known investors
PhotoPharmics is a clinical-stage medical device company developing non-invasive, light-based photo-neuromodulation therapies for neurodegenerative disease, with a focus on Parkinson's disease. Its investigational device Celeste delivers light through the eyes at home and is being evaluated in clinical trials targeting non-motor symptoms such as sleep, fatigue, and mood.
Founders & leadership
KS
Kent SavageNamed on SEC filing
Board
GC
TS
Ted StanleyBoard director
DA
Daniel AdamsBoard director
Investors · 1
Funding
SEC filings, press & company announcements$42.4M disclosed across 6 of 7 rounds · 2015–2025
- Undisclosed amountSeries B extensionApr 2025Source ↗
▶$26.2MraisedNov 2025 · 47 investors · BiotechnologyRule 506(b)
▶$26.2MraisedNov 2025 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $26.3M
- Amount sold
- $26.2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedDec 2020 · 9 investors · Other TechnologyRule 506(b)
▶$2.5MraisedDec 2020 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedOct 2019 · 24 investors · Other TechnologyRule 506(b)
▶$6.6MraisedOct 2019 · 24 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMar 2017 · 18 investors · Other TechnologyRule 506(b)
▶$2.7MraisedMar 2017 · 18 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kent SavageExecutive Officer, Director
- Ted StanleyDirector
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Offering amount
- $2.8M
- Amount sold
- $2.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2017 · 15 investors · Other TechnologyRule 506(b)
▶$2.3MraisedFeb 2017 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ted StanleyDirector
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJul 2015 · 15 investors · Other TechnologyRule 506(b)
▶$2.1MraisedJul 2015 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ted StanleyDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $2.7M
- Amount sold
- $2.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $320K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Photopharmics do?
- PhotoPharmics is a clinical-stage medical device company developing non-invasive, light-based photo-neuromodulation therapies for neurodegenerative disease, with a focus on Parkinson's disease. Its investigational device Celeste delivers light through the eyes at home and is being evaluated in clinical trials targeting non-motor symptoms such as sleep, fatigue, and mood.
- Who are Photopharmics's investors?
- Photopharmics's investors include Kickstart.
- How much funding has Photopharmics raised?
- Photopharmics has disclosed $42.4M raised across 6 of its 7 known rounds.
- Where is Photopharmics headquartered?
- Photopharmics is headquartered in Salt Lake City, US.